From Washington DC,

• STAT News tells us
  • “A new bill set to be considered on Wednesday by the House Ways & Means Committee would extend for two years telehealth flexibilities for Medicare enrollees that were adopted during the Covid-19 pandemic, and look to reform drug industry middlemen to pay for it. [FEHBlog note — The bill focuses on PBMs serving Medicare Prescription Drug Plans.]
  • “At the end of the official public health emergency, Congress extended flexibilities that changed where and what kinds of care people could receive over telehealth, but those rules are set to expire at the end of the year.  * * *
  • “Lawmakers discussed reforming PBMs in spending talks earlier this year, but ultimately failed to come to an agreement. The December deadline will be another chance for Congress to take action. * * *
  • “The new bill language will be marked up by lawmakers and may be subject to changes before it receives a vote. A likely path to passage is inclusion in a year-end spending package.”

• AP reports,
  • “The go-broke dates for Medicare and Social Security have been pushed back as an improving economy has contributed to changed projected depletion dates, according to the annual Social Security and Medicare trustees report Monday.
  • “Still, officials warn that policy changes are needed lest the programs become unable to pay full benefits to retiring Americans. 
  • “Medicare’s go-broke date for its hospital insurance trust fund was pushed back five years to 2036 in the latest report, thanks in part to higher payroll tax income and lower-than-projected expenses from last year. * * *
  • “Meanwhile, Social Security’s trust funds — which cover old age and disability recipients — will be unable to pay full benefits beginning in 2035, instead of last year’s estimate of 2034. Social Security would only be able to pay 83% of benefits.”

• The New York Times relates,
  • “The White House has unveiled tighter rules for research on potentially dangerous microbes and toxins, in an effort to stave off laboratory accidents that could unleash a pandemic.
  • “The new policy, published Monday evening, arrives after years of deliberations by an expert panel and a charged public debate over whether Covid arose from an animal market or a laboratory in China. * * *
  • “The new policy, which applies to research funded by the federal government, strengthens the government’s oversight by replacing a short list of dangerous pathogens with broad categories into which more pathogens might fall. The policy pays attention not only to human pathogens, but also those that could threaten crops and livestock. And it provides more details about the kinds of experiments that would draw the attention of government regulators.
  • “The rules will take effect in a year, giving government agencies and departments time to update their guidance to meet the new requirements.”

From the public health and medical research front,

• May 7 is National Fentanyl Awareness Day.

• EHS Today adds,
  • “With the FDA’s approval of naloxone as an OTC drug, workplaces now have access to a lifesaving tool. and therefore, it should be included in workplace first aid kits, says the International Safety Equipment Association (ISEA). ISEA publishes the ANSI/ISEA Z308.1-2021 standard.
  • “According to the U.S. Bureau of Labor Statistics, 525 people died from overdoses at work in 2022
  • “In a March 2024 statement, the White House challenged leaders to increase training and access to opioid overdose reversal medications, keeping the medications in first aid kits, and distributing the medications to employees and customers so they might save a life at home, work, or in their communities.”  

• Medscape informs us,
  • “All obesity interventions eventually lead to a plateau in weight, where further loss ceases despite ongoing efforts. But the duration of continuous weight loss before hitting a plateau is longer with both glucagon-like peptide 1 (GLP-1) receptor agonist drugs and gastric bypass surgery than with dietary restriction, primarily because they alter how weight loss affects appetite, not energy expenditure.
  • “That’s the conclusion from a new mathematical modeling study based on published data. The study showed that both GLP-1 agonists and Roux-en-Y gastric bypass (RYGB) surgery act to weaken the increase in appetite that normally occurs with time after weight loss attained through dietary restriction alone.
  • “The average time to weight loss plateau occurred within 12 months with dietary restriction vs 24 months in studies of tirzepatide (a dual glucose-dependent insulinotropic polypeptide/GLP-1 agonist), semaglutide, and RYGB, according to Kevin D. Hall, PhD, chief of the integrative physiology section at the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
  • “The findings were published in Obesity.
  • “Both RYGB and tirzepatide resulted in greater weight loss than semaglutide, but plateau timing of the three was roughly the same at 24 months. “The timing of the plateau is a different question than how much weight they lost,” Hall told Medscape Medical News.”

From the U.S. healthcare business front,

• Beckers Hospital Review lets us know,
  • “Dallas-based Steward Health Care has placed its 31 U.S. hospitals up for purchase to help offload its $9 billion debt after the health system filed for Chapter 11 bankruptcy, Reuters first reported May 7.
  • “During a court hearing May 7 in Houston, Steward attorney Ray Schrock told U.S. Bankruptcy Judge Chris Lopez that the for-profit health system is aiming to keep all of its hospitals open and to finalize the sale of the facilities by the end of this summer, the news agency reported.
  • “Our goal remains that there are zero hospitals closed on our watch,” Mr. Schrock said, according to Reuters. “There’s going to be a change in ownership in many hospitals, we recognize that. But we don’t want to see any of these communities fail to be served.”

• Healthcare Dive offers more details on this bankruptcy proceeding.

• Per Fierce Healthcare,
  • “Telehealth company Amwell continues to struggle in the stock market, and both its bottom- and top-line results in the first quarter missed Wall Street analysts’ estimates.
  • “The company, formerly American Well, brought in revenue of $59.5 million in the first quarter, down 7% from $64 million a year ago, and it reported a quarterly loss of $73.4 million, according to its first-quarter financial results (PDF). That compares to a loss of $398 million during the same quarter last year when it took a hefty impairment charge as a result of its stock market performance. * * *
  • “But, the virtual care giant is plotting accelerated revenue growth and a path to EBITDA profitability in 2026, boosted by a major contract with the Defense Health Agency (DHA).”